Objective: to present our experience with the treatment of hepatolithiasis.
Experimental Design: a retrospective study. Every patient operated on during 2002-2004.
Results: mean age was 68.2 years. All patients were male. Two patients had been operated on before. The other three suffered from: monolobar Caroli s disease (1), cholangiocarcinoma (1), and hepatolihtiasis without clear etiologic factors (1). All of them had intrahepatic and extrahepatic litihiasis. Clinical signs included: pain in RUQ, fever, and jaundice. Bilirubin was 3.5 mg/dl (min: 1.7, max: 5.9), GGT: 676.2 IU/l (min: 29, max: 2039), and alkaline phosphatase: 400 IU/l (min: 100, max: 1136). Abdominal ultrasounds always correctly diagnosed HL. CT (3 patients) only diagnosed one case. ERCP (3 patients) and cholangio-MRI (2 patients) always diagnosed HL correctly. Surgical procedures were: hepatojejunostomy with lavage of bile duct (2 cases) and hepatectomy (3 cases) -both right (1) and left (2). We always performed an intraoperative ultrasonography and choledoscopy. Morbidity was: biliary fistula (1 case) treated by percutaneous drainage. No mortality occurred. Median stay was 8.8 days. Mean follow-up is 12 months (min: 11, max: 20). No relapse has been observed.
Conclusions: HL is infrequent in Spain. Surgical treatment, usually liver resection, obtains good results with low morbidity and mortality.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4321/s1130-01082006000800005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeted locus amplification to develop robust patient-specific assays for liquid biopsies in pediatric solid tumors.
Front Oncol
April 2023
Princess Máxima Center for Pediatric Oncology Research, Utrecht, Netherlands.
Background: Liquid biopsies combine minimally invasive sample collection with sensitive detection of residual disease. Pediatric malignancies harbor tumor-driving copy number alterations or fusion genes, rather than recurrent point mutations. These regions contain tumor-specific DNA breakpoint sequences.
View Article and Find Full Text PDFElevated enhancer-oncogene contacts and higher oncogene expression levels by recurrent CTCF inactivating mutations in acute T cell leukemia.
Cell Rep
April 2023
Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Electronic address:
Monoallelic inactivation of CCCTC-binding factor (CTCF) in human cancer drives altered methylated genomic states, altered CTCF occupancy at promoter and enhancer regions, and deregulated global gene expression. In patients with T cell acute lymphoblastic leukemia (T-ALL), we find that acquired monoallelic CTCF-inactivating events drive subtle and local genomic effects in nearly half of t(5; 14) (q35; q32.2) rearranged patients, especially when CTCF-binding sites are preserved in between the BCL11B enhancer and the TLX3 oncogene.
View Article and Find Full Text PDFRobust detection of translocations in lymphoma FFPE samples using targeted locus capture-based sequencing.
Nat Commun
June 2021
Oncode Institute & Hubrecht Institute-KNAW and University Medical Center Utrecht, Utrecht, the Netherlands.
Article Synopsis
- In routine pathology, cancer biopsies are preserved using formalin-fixed, paraffin-embedding (FFPE) techniques, but this process causes DNA fragmentation, making it difficult to analyze chromosomal rearrangements crucial for cancer diagnosis and treatment.
- The new method presented, FFPE-targeted locus capture (FFPE-TLC), targets sequencing of specific rearrangements in FFPE samples, allowing for deeper insights into previously unknown rearrangements.
- FFPE-TLC has proven to be more sensitive and specific than traditional methods like fluorescence in situ hybridization (FISH) and standard capture-NGS, making it a significant advancement for accurate cancer diagnostics in preserved tissue samples.
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.
Hematol Oncol
August 2021
Department of Molecular Biotechnology and Health Sciences, Division of Hematology, University of Torino, Torino, Italy.
Minimal residual disease (MRD) monitoring by PCR methods is a strong and standardized predictor of clinical outcome in mantle cell lymphoma (MCL) and follicular lymphoma (FL). However, about 20% of MCL and 40% of FL patients lack a reliable molecular marker, being thus not eligible for MRD studies. Recently, targeted locus amplification (TLA), a next-generation sequencing (NGS) method based on the physical proximity of DNA sequences for target selection, identified novel gene rearrangements in leukemia.
View Article and Find Full Text PDFEnhanced CHO Clone Screening: Application of Targeted Locus Amplification and Next-Generation Sequencing Technologies for Cell Line Development.
Biotechnol J
July 2019
Novartis Institutes for BioMedical Research, Integrated Biologics Profiling Unit, CH-4002, Basel, Switzerland.
Early analytical clone screening is important during Chinese hamster ovary (CHO) cell line development of biotherapeutic proteins to select a clonally derived cell line with most favorable stability and product quality. Sensitive sequence confirmation methods using mass spectrometry have limitations in throughput and turnaround time. Next-generation sequencing (NGS) technologies emerged as alternatives for CHO clone analytics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!